Pulmonary hypertension, determined noninvasively by tricuspid regurgitant jet velocity on Doppler echocardiography, was previously identified in 25% of long-term survivors who received chest-directed radiotherapy. To validate noninvasively defined pulmonary hypertension, survivors (mean age 48 years), exposed to chest radiotherapy, underwent right heart catheterization with planned cardiopulmonary exercise testing during catheterization. Eight participants had an elevated mean pulmonary artery pressure at rest (≥25 mm Hg) or with subsequent exercise (>30 mm Hg), evidence of hemodynamically confirmed pulmonary hypertension by right heart catheterization. Cardiopulmonary exercise testing further defined the magnitude and etiology of cardiopulmonary limitations in this life-threatening late effect.
INTRODUCTION
Adult survivors of childhood cancer exposed to chest-directed radiotherapy and anthracycline chemotherapy have a significant lifetime risk for cardiotoxicity and cardiac mortality. [1] [2] [3] [4] [5] We previously identified, by two-dimensional and Doppler echocardiography, pulmonary hypertension as estimated by tricuspid regurgitant jet velocity (TRV) > 2.8 m/sec, in 25% of survivors who received chest radiotherapy and evidence for a significant radiation dose-response relationship. 6 However, to our knowledge, neither invasive assessment with right heart catheterization, the reference standard to validate the diagnosis of pulmonary hypertension, nor exercise to induce mild pulmonary hypertension during catheterization has been prospectively, systematically assessed in this population. Furthermore, among pediatric Abbreviations: TRV, tricuspid regurgitant jet velocity cancer survivors the nature of pulmonary hypertension, whether due to pulmonary arterial hypertension or pulmonary venous hypertension (i.e., from primarily a cardiac source), is unknown. Understanding this potential difference in etiology is essential to direct appropriate future therapies. 7 
METHODS
Details of eligibility, recruitment, and study design have been previously published. 8 To be eligible for right heart catheterization, survivors had to have TRV > 2.8 m/sec on screening 2D-Echo and significant exercise limitation with dyspnea during a 6-min walk and <600 m of exercise tolerance. Fourteen patients agreed to screening for eligibility, two were found to be ineligible (TRV < 2.8 m/sec), and two had scheduling conflicts, resulting in 10 participants in which right heart catheterization was performed, with six completing simultaneous cardiopulmonary exercise testing.
After informed consent was obtained, radial artery and right internal jugular catheters were placed in a sterile fashion with modified Seldinger technique. To identify pulmonary hypertension, defined as an elevated mean pulmonary artery pressure at rest (≥25 mm Hg) or with subsequent exercise (>30 mm Hg), pressures were obtained from the radial artery, right atrium, and pulmonary artery as well as measurement of the pulmonary capillary wedge pressure, an indirect measure of left atrial pressure, with cardiac output determined by thermodilution and Fick methods. Participants who could tolerate exercise (n = 6) completed a single bout of maximum incremental cardiopulmonary exercise testing on an electronically braked cycle ergometer (Ergoline) until maximal symptom-limited effort was obtained. Pulmonary gas exchange and minute ventilation were measured breath by breath with a commercially available metabolic cart (CareFusion). 9 Two minutes of rest were followed by 2 min of unloaded cycling. Work was then continually increased by 6.25-25 W/min. To identify a primary cardiac etiology (i.e., pulmonary venous hypertention), end expiratory pulmonary capillary wedge pressure was obtained at rest, supine and then upright, and with 2-min intervals during exercise. Blood specimens were drawn at rest and during the last 15 sec of each 2 min of exercise, until cessation of exercise at maximal symptom-limited effort. 9 The protocol was approved at both institutional review boards.
RESULTS
Ten survivors (age range 36-55 years, five female; Table 1 ) previously treated with chest radiotherapy (dose range 20-39.5 Gy) completed right heart catheterization. Each had a history of cardiac and/or pulmonary disease including eight with moderate or significant valvular heart disease, three with complete heart block and three with radiographic evidence of pulmonary fibrosis. Based upon the screening 2D-Echo measurement of TRV, the estimated pulmonary artery pressure ranged from 32 to 62 mm Hg though nine of 10 participants had a left ventricular ejection fraction >50% by biplane Simpson's method.
The baseline right heart catheterization in supine and upright positions was well tolerated and identified pulmonary hypertension (mean pulmonary artery ≥25 mm Hg) in seven of 10 survivors with an elevated pulmonary capillary wedge pressure (≥12 mm Hg).
Six survivors successfully completed cardiopulmonary exercise testing (two were unable to complete due to baseline need for nasal cannula oxygenation; exercise equipment was not available for two others), four of whom had an elevated mean pulmonary artery pressure on baseline supine right heart catheterization. Two of these six who completed cardiopulmonary exercise testing (participant no. 2 and 4, Table 1), had an elevated pulmonary capillary wedge pressure as well as an abnormal elevation of pulmonary vascular resistance at peak exercise identifying a mixed etiology (i.e., evidence for both pulmonary venous hypertension and pulmonary arterial hypertension) for pulmonary hypertension. Both of these patients had a previous diagnosis of pulmonary fibrosis. Among two other participants who completed cardiopulmonary exercise testing, with a normal supine and upright right heart catheterization at rest (participants no. 9 and 10), one (no. 10) had a marked elevation of the mean pulmonary artery pressure identified only at peak exercise. This participant also had an elevated pulmonary capillary wedge pressure. Additionally, one survivor (no. 6) who was unable to complete cardiopulmonary exercise testing did receive a 500 ml intravenous fluid challenge, resulting in a significant increase in mean pulmonary artery and pulmonary capillary wedge pressure strongly suggesting impairment in left ventricular diastolic filling. Therefore, with additional exercise testing a total of eight participants were validated to have pulmonary hypertension (seven by standard catheterization, one additional participant induced by exercise). Furthermore, while all had evidence of a cardiac etiology (i.e., pulmonary venous hypertension), only two of these had additional evidence for pulmonary injury (i.e., pulmonary arterial hypertension).
Finally, the use of cardiopulmonary exercise testing identified three childhood cancer survivors (no. 1, 8, and 10) who had an abnormal systemic hypertensive response to exercise, with evidence of deconditioning and chronotropic incompetence that lead to important cardiac limitations.
DISCUSSION
The findings of our current study support and extend the results of our previous report in which we noninvasively identified pulmonary hypertension in 25% of survivors exposed to chest-directed radiotherapy. Using prospective, systematic validation coupled with hemodynamic measurements, we confirmed that eight of 10 childhood cancer survivors with echocardiographic evidence of pulmonary hypertension had elevated pulmonary artery pressures. 2 Seven of these cases would have had pulmonary hypertension confirmed by routine supine catheterization. Additional exercise challenge resulted in elevated mean pulmonary artery pressure in one participant. Overall, eight of 10 participants had a substantial primary cardiac limitation to exercise (i.e., pulmonary venous hypertension) with two of these having a mixed etiology of pulmonary hypertension (a combination of pulmonary arterial hypertension and pulmonary venous hypertension). 10 In this population with complex cardiac and pulmonary disease (valvular, coronary artery, cardiomyopathy, rhythm disturbances, pulmonary fibrosis), the addition of cardiopulmonary ALL, acute lymphoblastic leukemia; BP, systemic blood pressure; bpm, beats per minute; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EF, left ventricular ejection fraction; m, meters; F, female; Gy, Gray; HL, Hodgkin lymphoma; HF, heart failure (previous EF < 45%); HTN, hypertension; M, male; NA, exercise testing not available at time of catheterization; NB, neuroblastoma; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PF, pulmonary fibrosis; PVR, pulmonary vascular resistance; Qmax, maximum cardiac output; QTc, prolonged corrected QT interval; RAP, right atrial pressure; RT, radiation therapy; RVEF, right ventricular ejection fraction; TR Jet = tricuspid regurgitant jet; U = unable to complete due to use of oxygen.
screening. 15 For this high-risk population of survivors with an echodefined TRV > 2.8 m/sec, general population guidelines recommending right heart catheterization to confirm this diagnosis should be followed. 16 In the current experience, the addition of cardiopulmonary exercise testing further defined the etiology of pulmonary hypertension, providing information to guide therapeutic decision making.
